Skip to main content
. 2022 Mar 18;12(3):e058363. doi: 10.1136/bmjopen-2021-058363

Table 4.

ORs from logistic regression models testing the association of specific statins compared with no statin with adverse 30-day outcomes among VHA veterans with a positive respiratory swab for SARS-CoV-2, n=231 017

Hospital admission ICU admission Death
OR 95% CI P value OR 95% CI P value OR 95% CI P value
No statin ref ref ref
Atorvastatin 0.98 0.95 to 1.01 0.136 0.96 0.9 to 1.02 0.194 0.8 0.76 to 0.84 <0.001
Fluvastatin 1.47 0.45 to 4.82 0.524 1.79 0.23 to 13.8 0.577 0.55 0.07 to 4.43 0.575
Lovastatin 0.73 0.57 to 0.93 0.012 0.48 0.26 to 0.9 0.022 0.64 0.45 to 0.91 0.013
Pitavastatin 0.45 0.16 to 1.26 0.128 0.66 0.09 to 4.8 0.679 0.82 0.25 to 2.68 0.738
Pravastatin 0.93 0.86 to 1 0.045 0.94 0.81 to 1.1 0.443 0.78 0.7 to 0.87 <0.001
Rosuvastatin 0.81 0.76 to 0.86 <0.001 0.82 0.72 to 0.93 0.002 0.72 0.65 to 0.79 <0.001
Simvastatin 0.91 0.86 to 0.97 0.001 0.91 0.8 to 1.02 0.107 0.77 0.71 to 0.84 <0.001
Sex at birth, female 0.75 0.71 to 0.8 <0.001 0.74 0.65 to 0.84 <0.001 0.57 0.5 to 0.65 <0.001
Age category, years
 19–39 0.61 0.58 to 0.66 <0.001 0.6 0.51 to 0.71 <0.001 0.15 0.11 to 0.21 <0.001
 40–49 0.75 0.71 to 0.8 <0.001 0.68 0.59 to 0.79 <0.001 0.38 0.3 to 0.48 <0.001
 50–59 ref ref ref
 60–69 1.28 1.23 to 1.34 <0.001 1.32 1.21 to 1.45 <0.001 2.85 2.55 to 3.2 <0.001
 70–79 1.43 1.36 to 1.49 <0.001 1.49 1.36 to 1.64 <0.001 5.92 5.31 to 6.6 <0.001
 ≥80 1.81 1.71 to 1.91 <0.001 1.62 1.45 to 1.82 <0.001 13.86 12.37 to 15.54 <0.001
White (vs not white) 0.88 0.81 to 0.97 0.007 0.75 0.61 to 0.91 0.004 0.88 0.74 to 1.04 0.121
Black (vs not black) 1.36 1.24 to 1.5 <0.001 1.1 0.89 to 1.35 0.39 0.78 0.66 to 0.94 0.007
Hispanic (vs not Hispanic) 1.16 1.1 to 1.22 <0.001 1.03 0.92 to 1.15 0.633 1.13 1.04 to 1.24 0.007
Body mass index category, kg/m²
 <18.5 1.15 1.02 to 1.29 0.025 1.35 1.06 to 1.73 0.015 1.82 1.59 to 2.08 <0.001
 18.5–24.9 ref ref ref
 25–29.9 0.81 0.78 to 0.85 <0.001 0.89 0.82 to 0.97 0.006 0.73 0.68 to 0.79 <0.001
 30–34.9 0.76 0.73 to 0.8 <0.001 0.88 0.81 to 0.97 0.006 0.68 0.64 to 0.74 <0.001
 35–39.9 0.76 0.72 to 0.8 <0.001 0.85 0.76 to 0.94 0.002 0.64 0.59 to 0.7 <0.001
 ≥40 0.87 0.81 to 0.92 <0.001 1.03 0.91 to 1.16 0.675 0.79 0.72 to 0.88 <0.001
Tobacco use
 Never ref
 Former 1.11 1.08 to 1.15 <0.001 1.1 1.02 to 1.17 0.01 1.18 1.12 to 1.24 <0.001
 Current 1.39 1.35 to 1.44 <0.001 1.29 1.2 to 1.39 <0.001 1.24 1.17 to 1.32 <0.001
Urban/rural/highly rural residence
 Highly rural 0.57 0.5 to 0.66 <0.001 0.74 0.54 to 1 0.051 1.16 0.97 to 1.38 0.096
 Rural 0.7 0.68 to 0.72 <0.001 0.88 0.82 to 0.93 <0.001 1.04 0.99 to 1.08 0.14
 Urban ref ref ref
 Unknown 0.27 0.1 to 0.74 0.011 0.55 0.08 to 3.96 0.549 1.75 0.72 to 4.25 0.22
Diabetes 1.29 1.26 to 1.33 <0.001 1.26 1.19 to 1.33 <0.001 1.36 1.3 to 1.42 <0.001
Hypertension 1.3 1.25 to 1.35 <0.001 1.29 1.18 to 1.41 <0.001 0.96 0.9 to 1.02 0.149
Cardiovascular disease 1.84 1.78 to 1.89 <0.001 2.08 1.94 to 2.23 <0.001 1.24 1.18 to 1.3 <0.001
Heart failure 1.64 1.58 to 1.69 <0.001 1.53 1.43 to 1.63 <0.001 1.31 1.25 to 1.38 <0.001
Alcohol use disorder 0.75 0.73 to 0.78 <0.001 0.86 0.79 to 0.93 <0.001 0.69 0.64 to 0.73 <0.001
Estimated glomerular filtration rate, mL/min/1.73 m²
 ≥90 ref ref ref
 60–89 0.9 0.87 to 0.93 <0.001 0.96 0.88 to 1.04 0.273 1.1 1.02 to 1.18 0.018
 45–59 0.99 0.94 to 1.03 0.519 1 0.91 to 1.1 0.941 1.44 1.33 to 1.56 <0.001
 30–44 1.1 1.04 to 1.16 0.001 1.15 1.02 to 1.29 0.024 1.83 1.68 to 1.99 <0.001
 15–29 1.31 1.21 to 1.42 <0.001 1.32 1.14 to 1.53 <0.001 2.65 2.36 to 2.97 <0.001
 <15 or dialysis 1.45 1.32 to 1.59 <0.001 1.51 1.29 to 1.77 <0.001 2.48 2.16 to 2.84 <0.001

Models additionally adjusted for month of diagnosis and geographic location by Veterans Integrated Service Network location; not adjusted for the presence of an active statin prescription 6 months prior to enrolment.

ICU, intensive care unit; VHA, Veterans Health Administration.